Contact
searchSearch
HMP Global
Login

Tardive Dyskinesia Topic Center

doctor holds hand of older patient
News
Valbenazine Effective for Long-Term Treatment of TD in Older Adults, Analysis Finds
05/21/2025
Maria Mantas
A post hoc analysis found that valbenazine was safe and effective for the long-term treatment of tardive dyskinesia (TD) in adults aged 65 and older.
A post hoc analysis found that valbenazine was safe and effective for the long-term treatment of tardive dyskinesia (TD) in adults aged 65 and older.
A post hoc analysis found that...
05/21/2025
Psych Congress Network
poster presentation session at a conference
Conference Coverage
Deutetrabenazine Targets VMAT2 With Precision, Analysis Finds
05/12/2025
Jolynn Tumolo
Deutetrabenazine showed significant efficacy and high specificity in inhibiting its primary target, VMAT2,, in functional assessments of the drug’s deuterated metabolites. Findings were reported at the inaugural poster session at the NEI...
Deutetrabenazine showed significant efficacy and high specificity in inhibiting its primary target, VMAT2,, in functional assessments of the drug’s deuterated metabolites. Findings were reported at the inaugural poster session at the NEI...
Deutetrabenazine showed...
05/12/2025
Psychiatry & Behavioral Health
From Psychiatry & Behavioral Health
Patient survey
News
Patient Survey Identifies Barriers to TD Treatment
11/06/2024
Jolynn Tumolo
Key barriers to tardive dyskinesia (TD) diagnosis include a lack of communication with the health care professional, lack of a physical exam, and low educational and socioeconomic status, according to a survey of adults with TD symptoms.
Key barriers to tardive dyskinesia (TD) diagnosis include a lack of communication with the health care professional, lack of a physical exam, and low educational and socioeconomic status, according to a survey of adults with TD symptoms.
Key barriers to tardive...
11/06/2024
Psych Congress Network
: FDA Approves Oral Valbenazine Granule Formulation, an Alternative Administration Option for Adults With TD
News
FDA Approves Oral Valbenazine Granule Formulation, an Alternative Administration Option for Adults With TD
05/15/2024
Evi Arthur
At the end of April, Neurocrine Biosciences, Inc. announced the approval of INGREZZA® SPRINKLE (valbenazine) capsules by the FDA. This approval provides an alternative option for patients with dysphagia or who have difficulty swallowing. 
At the end of April, Neurocrine Biosciences, Inc. announced the approval of INGREZZA® SPRINKLE (valbenazine) capsules by the FDA. This approval provides an alternative option for patients with dysphagia or who have difficulty swallowing. 
At the end of April, Neurocrine...
05/15/2024
Psych Congress Network
TD Has ‘Severe Impact’ on Patients and Caregivers
News
TD Has ‘Severe Impact’ on Patients and Caregivers
05/10/2024
Evi Arthur
Tardive dyskinesia (TD) was found to have a “severe impact” on the lives of both patients and their caregivers across physical, psychological, and social domains. Results from the survey-based study were published in the Journal of Patient...
Tardive dyskinesia (TD) was found to have a “severe impact” on the lives of both patients and their caregivers across physical, psychological, and social domains. Results from the survey-based study were published in the Journal of Patient...
Tardive dyskinesia (TD) was...
05/10/2024
Psych Congress Network
Geriatric Patient with son in long term care setting
News
High Comorbidity, Polypharmacy Burden in Patients With Tardive Dyskinesia in LTC Settings
05/07/2024
Jolynn Tumolo
Patients with tardive dyskinesia (TD) in long-term care settings have a high comorbidity and polypharmacy burden, with half taking medications that may worsen TD, according to a poster presentation at the APA annual meeting.
Patients with tardive dyskinesia (TD) in long-term care settings have a high comorbidity and polypharmacy burden, with half taking medications that may worsen TD, according to a poster presentation at the APA annual meeting.
Patients with tardive dyskinesia...
05/07/2024
Psych Congress Network
Amber Hoberg, MSN, APRN, PMHNP-BC
Videos
Clinical Pearls to Enhance Tardive Dyskinesia Treatment
01/10/2024
Amber Hoberg, MSN, APRN, PMHNP-BC
n this video, Tardive Dyskinesia Section Editor Amber Hoberg, MSN, APRN, PMHNP-BC, of Med Management Associates, offers clinical pearls that clinicians can implement to optimize their tardive dyskinesia care.
n this video, Tardive Dyskinesia Section Editor Amber Hoberg, MSN, APRN, PMHNP-BC, of Med Management Associates, offers clinical pearls that clinicians can implement to optimize their tardive dyskinesia care.
n this video, Tardive Dyskinesia...
01/10/2024
Psych Congress Network
amber hoberg, np
Expert Insights Quiz
What screeners should be used to diagnose tardive dyskinesia?
05/26/2023
True or False: According to Nurse Amber Hoberg, the AIMS is the only scale that should be used when screening a patient for tardive dyskinesia (TD).
True or False: According to Nurse Amber Hoberg, the AIMS is the only scale that should be used when screening a patient for tardive dyskinesia (TD).
True or False: According to...
05/26/2023
Psych Congress Network
Elderly patient and his doctor
News
Awareness of TD Symptoms Linked With Poorer Health, Social Functioning in Patients
05/15/2023
Jolynn Tumolo
Clinician-confirmed possible tardive dyskinesia (TD) was associated with diminished wellness and social functioning in real-world patients, according to a study published online in the Journal of Patient-Reported Outcomes.
Clinician-confirmed possible tardive dyskinesia (TD) was associated with diminished wellness and social functioning in real-world patients, according to a study published online in the Journal of Patient-Reported Outcomes.
Clinician-confirmed possible...
05/15/2023
Psych Congress Network
quiz
Expert Insights Quiz
How does tardive dyskinesia impact medication adherence?
02/14/2023
True or false: Patients with Tardive Dyskinesia (TD) have high rates of antipsychotic medication non-adherence partly due to their TD symptoms.
True or false: Patients with Tardive Dyskinesia (TD) have high rates of antipsychotic medication non-adherence partly due to their TD symptoms.
True or false: Patients with...
02/14/2023
Psych Congress Network
Chepke
Expert Insights Quiz
What is the next step if a patient taking antipsychotics exhibits excessive blink rate?
12/16/2022
As a clinician, if you notice a patient who is taking antipsychotics is exhibiting an excessive blink rate, what should the next step be?
As a clinician, if you notice a patient who is taking antipsychotics is exhibiting an excessive blink rate, what should the next step be?
As a clinician, if you notice a...
12/16/2022
Psych Congress Network

News

doctor holds hand of older patient
News
Valbenazine Effective for Long-Term Treatment of TD in Older Adults, Analysis Finds
05/21/2025
Maria Mantas
A post hoc analysis found that valbenazine was safe and effective for the long-term treatment of tardive dyskinesia (TD) in adults aged 65 and older.
A post hoc analysis found that valbenazine was safe and effective for the long-term treatment of tardive dyskinesia (TD) in adults aged 65 and older.
A post hoc analysis found that...
05/21/2025
Psych Congress Network
poster presentation session at a conference
Conference Coverage
Deutetrabenazine Targets VMAT2 With Precision, Analysis Finds
05/12/2025
Jolynn Tumolo
Deutetrabenazine showed significant efficacy and high specificity in inhibiting its primary target, VMAT2,, in functional assessments of the drug’s deuterated metabolites. Findings were reported at the inaugural poster session at the NEI...
Deutetrabenazine showed significant efficacy and high specificity in inhibiting its primary target, VMAT2,, in functional assessments of the drug’s deuterated metabolites. Findings were reported at the inaugural poster session at the NEI...
Deutetrabenazine showed...
05/12/2025
Psychiatry & Behavioral Health
Patient survey
News
Patient Survey Identifies Barriers to TD Treatment
11/06/2024
Jolynn Tumolo
Key barriers to tardive dyskinesia (TD) diagnosis include a lack of communication with the health care professional, lack of a physical exam, and low educational and socioeconomic status, according to a survey of adults with TD symptoms.
Key barriers to tardive dyskinesia (TD) diagnosis include a lack of communication with the health care professional, lack of a physical exam, and low educational and socioeconomic status, according to a survey of adults with TD symptoms.
Key barriers to tardive...
11/06/2024
Psych Congress Network
: FDA Approves Oral Valbenazine Granule Formulation, an Alternative Administration Option for Adults With TD
News
FDA Approves Oral Valbenazine Granule Formulation, an Alternative Administration Option for Adults With TD
05/15/2024
Evi Arthur
At the end of April, Neurocrine Biosciences, Inc. announced the approval of INGREZZA® SPRINKLE (valbenazine) capsules by the FDA. This approval provides an alternative option for patients with dysphagia or who have difficulty swallowing. 
At the end of April, Neurocrine Biosciences, Inc. announced the approval of INGREZZA® SPRINKLE (valbenazine) capsules by the FDA. This approval provides an alternative option for patients with dysphagia or who have difficulty swallowing. 
At the end of April, Neurocrine...
05/15/2024
Psych Congress Network
TD Has ‘Severe Impact’ on Patients and Caregivers
News
TD Has ‘Severe Impact’ on Patients and Caregivers
05/10/2024
Evi Arthur
Tardive dyskinesia (TD) was found to have a “severe impact” on the lives of both patients and their caregivers across physical, psychological, and social domains. Results from the survey-based study were published in the Journal of Patient...
Tardive dyskinesia (TD) was found to have a “severe impact” on the lives of both patients and their caregivers across physical, psychological, and social domains. Results from the survey-based study were published in the Journal of Patient...
Tardive dyskinesia (TD) was...
05/10/2024
Psych Congress Network
Geriatric Patient with son in long term care setting
News
High Comorbidity, Polypharmacy Burden in Patients With Tardive Dyskinesia in LTC Settings
05/07/2024
Jolynn Tumolo
Patients with tardive dyskinesia (TD) in long-term care settings have a high comorbidity and polypharmacy burden, with half taking medications that may worsen TD, according to a poster presentation at the APA annual meeting.
Patients with tardive dyskinesia (TD) in long-term care settings have a high comorbidity and polypharmacy burden, with half taking medications that may worsen TD, according to a poster presentation at the APA annual meeting.
Patients with tardive dyskinesia...
05/07/2024
Psych Congress Network
Elderly patient and his doctor
News
Awareness of TD Symptoms Linked With Poorer Health, Social Functioning in Patients
05/15/2023
Jolynn Tumolo
Clinician-confirmed possible tardive dyskinesia (TD) was associated with diminished wellness and social functioning in real-world patients, according to a study published online in the Journal of Patient-Reported Outcomes.
Clinician-confirmed possible tardive dyskinesia (TD) was associated with diminished wellness and social functioning in real-world patients, according to a study published online in the Journal of Patient-Reported Outcomes.
Clinician-confirmed possible...
05/15/2023
Psych Congress Network
News
Valbenazine Use for Tardive Dyskinesia in Older Adults Proves Efficacious
12/08/2021
Heather Flint
Valbenazine use for tardive dyskinesia (TD) in adults aged 65 and older has been deemed efficacious with comparable outcomes to younger adults, according to a post hoc analysis.
Valbenazine use for tardive dyskinesia (TD) in adults aged 65 and older has been deemed efficacious with comparable outcomes to younger adults, according to a post hoc analysis.
Valbenazine use for tardive...
12/08/2021
Psych Congress Network
News
Deutetrabenazine is Beneficial for Long-Term Tardive Dyskinesia Treatment
12/03/2021
Meagan Thistle
Deutetrabenazine may provide long-term treatment benefits to patients with tardive dyskinesia (TD), according to a post hoc analysis presented in a poster at Psych Congress 2021.
Deutetrabenazine may provide long-term treatment benefits to patients with tardive dyskinesia (TD), according to a post hoc analysis presented in a poster at Psych Congress 2021.
Deutetrabenazine may provide...
12/03/2021
Psych Congress Network
News
Individual Titration of Deutetrabenazine Beneficial for Patients With Tardive Dyskinesia
11/17/2021
Erin McGuinness
Response-driven titration of deutetrabenazine is beneficial for patients with tardive dyskinesia (TD), according to new findings.
Response-driven titration of deutetrabenazine is beneficial for patients with tardive dyskinesia (TD), according to new findings.
Response-driven titration of...
11/17/2021
Psych Congress Network
An orange prescription container with generic pills spilling out in front of it
News
Antidepressant Use Not Linked to Worse Traumatic Brain Injury Outcomes
02/03/2026
Brionna Mendoza
A large nationwide cohort study found no evidence that preinjury antidepressant use increases short-term mortality, need for emergency brain surgery, or length of hospitalization following TBI.
A large nationwide cohort study found no evidence that preinjury antidepressant use increases short-term mortality, need for emergency brain surgery, or length of hospitalization following TBI.
A large nationwide cohort study...
02/03/2026
Psych Congress Network
A frustrated man works on a laptop
News
Frequent Generative AI Use Linked to Increased Depressive Symptoms
01/23/2026
Maria Mantas
Daily or more frequent generative AI use was associated with higher depressive symptom scores on the PHQ-9 compared with nonuse in a large US survey.
Daily or more frequent generative AI use was associated with higher depressive symptom scores on the PHQ-9 compared with nonuse in a large US survey.
Daily or more frequent...
01/23/2026
Psych Congress Network
a man holds his head in his hands
News
Cohort Study Finds Increased Suicide Risk in Survivors of Traumatic Injury
01/21/2026
Maria Mantas
Patients discharged alive after traumatic injury had a 9-fold higher risk of suicide than the general population 2 years after hospitalization, according to cohort study findings.
Patients discharged alive after traumatic injury had a 9-fold higher risk of suicide than the general population 2 years after hospitalization, according to cohort study findings.
Patients discharged alive after...
01/21/2026
Psych Congress Network
A man looks out a window
News
Adjunctive Vagus Nerve Stimulation Shows Durable Benefit in Treatment-Resistant Depression
01/20/2026
Maria Mantas
A long-term extension study found that adjunctive vagus nerve stimulation (VNS) had a durable benefit in patients with treatment-resistant major depression over 24 months.
A long-term extension study found that adjunctive vagus nerve stimulation (VNS) had a durable benefit in patients with treatment-resistant major depression over 24 months.
A long-term extension study...
01/20/2026
Psych Congress Network
a depressed teen adolescent holds head in hands crying upset sad major depression
News
Omega-3 Supplements Show No Benefit for Pediatric Major Depression in RCT
01/20/2026
Brionna Mendoza
A multicenter randomized clinical trial found that adding omega-3 fatty acid supplements to psychotherapy did not improve outcomes in children and adolescents with moderate-to-severe major depression.
A multicenter randomized clinical trial found that adding omega-3 fatty acid supplements to psychotherapy did not improve outcomes in children and adolescents with moderate-to-severe major depression.
A multicenter randomized...
01/20/2026
Psych Congress Network
brain
News
Several Noninvasive Brain Stimulation Modalities Show Benefit for Treatment-Resistant Schizophrenia
01/19/2026
Maria Mantas
A large network meta-analysis found specific noninvasive brain stimulation (NIBS) modalities improved symptoms in treatment-resistant schizophrenia (TRS).
A large network meta-analysis found specific noninvasive brain stimulation (NIBS) modalities improved symptoms in treatment-resistant schizophrenia (TRS).
A large network meta-analysis...
01/19/2026
Psych Congress Network
US FDA building
News
FDA Requests Removal of Suicide Risk Warnings From GLP-1 RA Labels
01/14/2026
Maria Mantas
The US Food and Drug Administration (FDA) has requested the removal of information regarding the risk of suicidal ideation and behaviors (SI/B) from the labeling of glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications.
The US Food and Drug Administration (FDA) has requested the removal of information regarding the risk of suicidal ideation and behaviors (SI/B) from the labeling of glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications.
The US Food and Drug...
01/14/2026
Psych Congress Network
illustration of a brain
News
Meta-Analysis Confirms Processing Speed as Core Cognitive Deficit in Schizophrenia
01/12/2026
Maria Mantas
Processing speed remains one of the most severely impaired cognitive domains in people with schizophrenia, according to a large systematic review and meta-analysis published in JAMA Psychiatry.
Processing speed remains one of the most severely impaired cognitive domains in people with schizophrenia, according to a large systematic review and meta-analysis published in JAMA Psychiatry.
Processing speed remains one of...
01/12/2026
Psych Congress Network
FDA building
News
FDA Approves At-Home Neuromodulation Therapy Device for Major Depression
01/12/2026
Maria Mantas
The US Food and Drug Administration has approved Proliv™Rx, a novel at-home neuromodulation therapy as adjunctive treatment for adults with major depressive disorder (MDD).
The US Food and Drug Administration has approved Proliv™Rx, a novel at-home neuromodulation therapy as adjunctive treatment for adults with major depressive disorder (MDD).
The US Food and Drug...
01/12/2026
Psych Congress Network
woman on a hill
News
Delay Discounting Fails to Predict Antidepressant Relapse in MDD
01/09/2026
Maria Mantas
A new multi-site study suggests that while delay discounting is elevated in patients with remitted MDD, it neither changes after antidepressant medication discontinuation nor predicts subsequent depressive relapse.
A new multi-site study suggests that while delay discounting is elevated in patients with remitted MDD, it neither changes after antidepressant medication discontinuation nor predicts subsequent depressive relapse.
A new multi-site study suggests...
01/09/2026
Psych Congress Network

Quizzes

amber hoberg, np
Expert Insights Quiz
What screeners should be used to diagnose tardive dyskinesia?
05/26/2023
True or False: According to Nurse Amber Hoberg, the AIMS is the only scale that should be used when screening a patient for tardive dyskinesia (TD).
True or False: According to Nurse Amber Hoberg, the AIMS is the only scale that should be used when screening a patient for tardive dyskinesia (TD).
True or False: According to...
05/26/2023
Psych Congress Network
quiz
Expert Insights Quiz
How does tardive dyskinesia impact medication adherence?
02/14/2023
True or false: Patients with Tardive Dyskinesia (TD) have high rates of antipsychotic medication non-adherence partly due to their TD symptoms.
True or false: Patients with Tardive Dyskinesia (TD) have high rates of antipsychotic medication non-adherence partly due to their TD symptoms.
True or false: Patients with...
02/14/2023
Psych Congress Network
Chepke
Expert Insights Quiz
What is the next step if a patient taking antipsychotics exhibits excessive blink rate?
12/16/2022
As a clinician, if you notice a patient who is taking antipsychotics is exhibiting an excessive blink rate, what should the next step be?
As a clinician, if you notice a patient who is taking antipsychotics is exhibiting an excessive blink rate, what should the next step be?
As a clinician, if you notice a...
12/16/2022
Psych Congress Network
tardive-dyskinesia-quiz
Quiz
The Impact of Tardive Dyskinesia Across Lifestyle Domains
12/10/2021
What percentage of patients with tardive dyskinesia reported their illness having a severe impact across their physical, psychological, and social lives? Take the quiz!
What percentage of patients with tardive dyskinesia reported their illness having a severe impact across their physical, psychological, and social lives? Take the quiz!
What percentage of patients with...
12/10/2021
Psych Congress Network
Quiz
Can long-term anticholinergic medication exposure cause long-term consequences?
10/28/2021
True or false: Long-term anticholinergic medication exposure can cause long-term consequences that surpass previously documented short-term cognitive effects.
True or false: Long-term anticholinergic medication exposure can cause long-term consequences that surpass previously documented short-term cognitive effects.
True or false: Long-term...
10/28/2021
Psych Congress Network
Quiz
Antibody Levels in Schizophrenia Patients With Tardive Dyskinesia
10/15/2021
According to a recent study, what antibody levels were significantly higher in schizophrenia patients with tardive dyskinesia (TD)? Take the quiz to find out!
According to a recent study, what antibody levels were significantly higher in schizophrenia patients with tardive dyskinesia (TD)? Take the quiz to find out!
According to a recent study,...
10/15/2021
Psych Congress Network
Quiz
Quiz: Are These Antibodies Associated with Orofacial Tardive Dyskinesia?
09/09/2021
True or False: A notable percentage of psychiatrists said they would use an anticholinergic medication to manage symptoms of tardive dyskinesia in a patient.
True or False: A notable percentage of psychiatrists said they would use an anticholinergic medication to manage symptoms of tardive dyskinesia in a patient.
True or False: A notable...
09/09/2021
Psych Congress Network
Bottles
Quiz
Updated Treatments for Tardive Dyskinesia
08/16/2021
What are the updated treatments for tardive dyskinesia? Take the quiz and find out!
What are the updated treatments for tardive dyskinesia? Take the quiz and find out!
What are the updated treatments...
08/16/2021
Psych Congress Network
quiz
Quiz
Did psychiatrists say they would use anticholinergic medication for TD treatment?
06/17/2021
True or False: A notable percentage of psychiatrists said they would use an anticholinergic medication to manage symptoms of tardive dyskinesia in a patient.
True or False: A notable percentage of psychiatrists said they would use an anticholinergic medication to manage symptoms of tardive dyskinesia in a patient.
True or False: A notable...
06/17/2021
Psych Congress Network
Quiz
How Often Should Patients Be Evaluated for Tardive Dyskinesia?
05/07/2021
Test your knowledge: How often does the American Psychiatric Association (APA) recommend patients taking either first or second-generation antipsychotics be assessed for tardive dyskinesia?
Test your knowledge: How often does the American Psychiatric Association (APA) recommend patients taking either first or second-generation antipsychotics be assessed for tardive dyskinesia?
Test your knowledge: How often...
05/07/2021
Psych Congress Network
a printed test, pencil, and clock on a desk
Quiz
Brain Aging in Schizophrenia
01/22/2026
Maria Mantas
Test your knowledge of recent research with this quick quiz!
Test your knowledge of recent research with this quick quiz!
Test your knowledge of recent...
01/22/2026
Psych Congress Network
An illustration of a pencil marking answers on a quiz sheet
Guidelines Quiz
Medication Monitoring in Patients With BPD
01/20/2026
Brionna Mendoza
Test your knowledge of APA guidelines with this quiz!
Test your knowledge of APA guidelines with this quiz!
Test your knowledge of APA...
01/20/2026
Psych Congress Network
Mark Olfson, MD, MPH
Quiz
Telemental Health Use Patterns
01/16/2026
Maria Mantas
Are you caught up with the latest research on telehealth use patterns?
Are you caught up with the latest research on telehealth use patterns?
Are you caught up with the...
01/16/2026
Psych Congress Network
illustration of a laptop screen displaying a test
Quiz
Stimulants and Psychosis Risk in ADHD
12/22/2025
Maria Mantas
Do you remember the findings from this systematic review?
Do you remember the findings from this systematic review?
Do you remember the findings...
12/22/2025
Psych Congress Network
Joseph Goldberg, MD
Quiz
Diagnosing Mixed Features in Bipolar Disorder
12/03/2025
Joseph F. Goldberg, MD
Test your knowledge with this quick quiz!
Test your knowledge with this quick quiz!
Test your knowledge with this...
12/03/2025
Psych Congress Network
Pop quiz written on a blackboard with white chalk
Quiz
Depression, Inflammation, and Insomnia
11/19/2025
Brionna Mendoza
Test your knowledge with this quiz!
Test your knowledge with this quiz!
Test your knowledge with this...
11/19/2025
Psych Congress Network
quiz
Quiz
Early Lead Exposure and Mental Health Outcomes
11/10/2025
Maria Mantas
Test your knowledge with this quick quiz!
Test your knowledge with this quick quiz!
Test your knowledge with this...
11/10/2025
Psych Congress Network
a teenager's hand putting a bag of white pills into another teenager's hand.
Quiz
Test Your Knowledge – Understanding Abuse Potential Across ADHD Therapies: What Clinicians Need to Know
10/23/2025
Curb misuse before it starts—test your diversion-prevention game in 3 quick questions.
Curb misuse before it starts—test your diversion-prevention game in 3 quick questions.
Curb misuse before it...
10/23/2025
Psych Congress Network
Edward Kaftarian, MD
Quiz
Building Patient Rapport in Telepsychiatry
10/09/2025
Edward Kaftarian, MD
Do you remember Dr Kaftarian's recommended strategies for building patient rapport via telehealth?
Do you remember Dr Kaftarian's recommended strategies for building patient rapport via telehealth?
Do you remember Dr Kaftarian's...
10/09/2025
Psych Congress Network
A woman sleeping peacefully
Quiz
Test Your Knowledge – ADHD and Sleep: Why Non-Stimulants Might Be the Right Choice (Part 3)
10/09/2025
Sleep and ADHD intersect—see if your management playbook is up to date in 3 quick questions.
Sleep and ADHD intersect—see if your management playbook is up to date in 3 quick questions.
Sleep and ADHD intersect—see if...
10/09/2025
Psych Congress Network

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use